Live Breaking News & Updates on Ab Science Stock Exchange

Stay updated with breaking news from Ab science stock exchange. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037

PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH PROTECTION UNTIL 2037 CANADIAN PATENT COMPLETES INTELLECTUAL. | June 1, 2023 ....

New Zealand , France General , South Korea , United States , Hong Kong , South Africa , European Medicines Agency , Health Canada , Drug Administration , Euronext Paris , Ab Science Stock Exchange , Press Release , Ompletes Ab Fr0010557264 ,

AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit

PRESS RELEASE AB SCIENCE SUMMARIZES KEY MESSAGES FROM ITS PARTICIPATION TO A PANEL DISCUSSION AT THE 2023 ALS DRUG DEVELOPMENT SUMMIT Paris, 17 May, 2023, 8:00pm CET AB Science SA today. | May 17, 2023 ....

United States , France General , Alain Moussy , Drug Development Summit , Drug Development , Panel Discussion , Drug Administration , Development Summit , Breakthrough Developments , Euronext Paris , Ab Science Stock Exchange , Press Release , Cience Ab Fr0010557264 ,

AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter

PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS RESUMED ITS REVIEW OF THE NEW DRUG SUBMISSION FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS, FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE. | May 9, 2023 ....

France General , United States , Alain Moussy , Health Canada , American Academy Of Neurology , New Drug Submission , American Academy , Euronext Paris , Ab Science Stock Exchange , Press Release , Creening Ab Fr0010557264 ,

AB Science reports its revenues for the year 2022 and provides an update on its activities

PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2022 AND THE KEY EVENTS OF THE PERIOD Financial information and other corporate. | April 28, 2023 ....

France General , United States , Alain Moussy , Health Canada , Enforcement Committee , Committee For Medicinal Products Human Use , Paris Court , European Medicines Agency , European Investment Bank , European Medicine Agency , French Medicine Agency , Drug Administration , Renewal Of The Programme , Augmentation De Capital , Alpha Blue , New Drug Submission , New Drug , Marketing Authorization , Medicinal Products , Human Use , Primary Progressive Multiple Sclerosis , Secondary Progressive Multiple Sclerosis , Expanded Disability Status Scale , Daily Living , Mini Mental State Examination , Capital Increase ,

AB Science announces the success of its capital increase by private placement for an amount of 15 million euros

PRESS RELEASE SUCCESS OF THE CAPITAL INCREASE BY PRIVATE PLACEMENT FOR AN AMOUNT OF 15 MILLION EUROS Paris, April 24, 2023, 8am CET AB Science S.A. , announces today the success of its capital. | April 24, 2023 ....

United States , France General , Alain Moussy , French Financial Market Authority , European Parliament , Chief Executive Officer , Capital Increase , French Commercial Code , French Monetary , Financial Code , Combined General Shareholder Meeting , New Shares , Euronext Paris , Member States , European Economic Area , Ab Science Stock Exchange , Press Release , Ts Ab Fr0010557264 ,